Zaheed Husain

Dr. Zaheed Husain is a cancer immunologist. He is the head of the Laboratory of Immunobiology in the Division of Interdisciplinary Medicine and Biotechnology at Harvard Medical School, Beth Israel Hospital, in Boston, MA and an instructor with the school’s Department of Medicine. He previously served for nearly a decade as the principal scientist and team leader in the immunology and oncology section of Wyeth Pharmaceuticals. At Wyeth, Dr. Husain was responsible for the discovery of EKI-785, a small molecule inhibitor of head and neck cancers; he subsequently led a research group of biologists and chemists responsible for filing the new drug with the Federal Drug Administration. His professional memberships include the American Association for the Advancement of Science (since 1989), the American Society of Cell Biology (since 2002), and the Federation of Clinical Immunology Societies (since 2008). Dr. Husain earned his Ph.D. in Molecular Biology and Biochemistry from New York University.